Cargando…
Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations
INTRODUCTION: Hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) is complement-mediated due to the lack of complement inhibitors in the hemopoietic cell membranes, making complement inhibition the best approach to manage PNH. Three complement inhibitors are approved by the European Medicines Age...
Autores principales: | Bodó, Imre, Amine, Ismail, Boban, Ana, Bumbea, Horia, Kulagin, Alexander, Lukina, Elena, Piekarska, Agnieszka, Zupan, Irena Preloznik, Sokol, Juraj, Windyga, Jerzy, Cermak, Jaroslav |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112829/ https://www.ncbi.nlm.nih.gov/pubmed/37072660 http://dx.doi.org/10.1007/s12325-023-02510-4 |
Ejemplares similares
-
Management of paroxysmal nocturnal hemoglobinuria (PNH)
por: Luzzatto, Lucio
Publicado: (2022) -
Autosplenectomy in a Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH)
por: Burns, Ethan, et al.
Publicado: (2019) -
Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH)
por: Lobry, Camille, et al.
Publicado: (2019) -
No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab
por: Alashkar, Ferras, et al.
Publicado: (2020) -
Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry
por: Jang, Jun Ho, et al.
Publicado: (2016)